Metastatic renal cancer (mrcc): Evidence-based treatment
|
|
- Matthew Small
- 5 years ago
- Views:
Transcription
1
2 Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, th ESO-ESMO Latin American Masterclass in Clinical Oncology
3 Disclosures Consulting: Bristol-Myers Squibb México Travel, Accommodations, Expenses: Bristol-Myers Squibb México, Novartis
4 Epidemiology worldwide 2012 Incidence 337,860 (2.4%) Mortality 143,406 (1.7%) 14º
5 Epidemiology in México Incidence 2,395 (3.7%) 8º Mortality 1,304 (3.4%)
6 Prognosis in kidney cancer Stage 5-Year Survival Rate I 81% II 74% III 53% IV 8%
7 Histopathology 10 tumor subtypes in the current WHO classification Clear cell (70%) Papillary Chromophobe 90% to 95% of renal carcinomas Collecting duct tumors Renal Cancer: Contemporary Management. Springer 2013
8 Risk Models
9 Prognostic Factors for mrcc Two scales largely used: 1. Memorial Sloan Kettering Cancer Center (MSKCC) 2. International mrcc Database Consortium (IMDC)
10 MSKCC model Developed from patients treated with IFN-based regimens. 1. Poor performance status (Karnofsky <80%) 2. Less than a 1-year interval from diagnosis to treatment 3. High serum lactate dehydrogenase (LDH) level (>1.5 UNL) 4. High serum calcium level (>10 mg/dl) 5. Low hemoglobin concentration Motzer. J Clin Oncol 2002
11 MSKCC model Risk group Favorable Intermediate Poor OS, median 30 months 14 months 5 months Motzer. J Clin Oncol 2002
12 IMDC model Developed from patients treated with VEGF-TARGETED therapies. 1. Poor performance status (Karnofsky <80%) 2. Less than a 1-year interval from diagnosis to treatment 3. High absolute neutrophil count 4. High platelet count 5. High serum calcium level (>10 mg/dl) 6. Low hemoglobin concentration Heng. Lancet Oncol 2013
13 IMDC model # risk factors Risk group OS, median 0 Favourable 43 months 1 2 Intermediate 22 months 3 Poor 8 months Heng. Lancet Oncol 2013
14 Importance of prognostication 1. Patient counseling 2. Clinical trial risk stratification 3. Planning therapy Heng. Eur Urol 2014
15 Treatment for mrcc
16 Treatment for mrcc 1. Surgical 2. Radiation therapy 3. Systemic therapy
17 Surgery in mrcc
18 Cytoreductive nephrectomy: IFN era Prospective phase 3 trials: Survival advantage over no surgery 11.1 months vs. 8.1 months p = months vs. 7.0 months p = 0.03 Flanigan. N Engl J Med 2001 Mickisch. Lancet 2001
19 Cytoreductive nephrectomy: targeted therapy era Retrospective analyses: Survival advantage over no surgery 17.1 months vs. 8.1 months 20.6 months vs. 9.6 months Hanna. J Clin Oncol 2016 Heng. Eur Urol 2014
20 Candidates for cytoreductive nephrectomy Most patients treated with targeted therapy EXCEPT (may not benefit from CN): 1. Patients with estimated survival times <12 months 2. or 4 IMDC prognostic factors Heng. Eur Urol 2014
21 Proposed decision-making strategy for the treatment of mrcc Kidney with primary tumor in place? Consider cytoreductive nephrectomy with or without metastasectomy Modified from: Motzer. NEJM 2017
22 Radiation therapy
23 Radiation therapy Radioresistant tumor Used for palliation of symptoms 30% of patients will require it for palliation Brain metastases Bone metastases Stereotactic ablative radiotherapy to metastatic sites? selected cases Shaikh. Urology 2015 Straka. J Clin Oncol 2013
24 Systemic therapy
25 Malignant solid-tumors systemic treatment: overview First-line treatment characteristics: 1. BEST overall response (OR) 2. BEST Progression-free survival (PFS) 3. BEST (if possible) Overall survival (OS) Exceptions: Toxicity Elderly McKibbin. Oncologist 2008
26 Therapies approved for mrcc (as march 2018) Axitinib Interleukin-2 Pazopanib Bevacizumab Interferon-alfa Sorafenib Cabozantinib Lenvatinib Sunitinib Everolimus Nivolumab Temsirolimus
27 Systemic therapies approved for mrcc Not everything is a phase 3 trial in mrcc Phase 2 approvals: Interleukin-2 Sunitinib Lenvatinib + everolimus Not all of the drugs have been compared with each other Fyfe. J Clin Oncol 1995 Motzer. J Clin Oncol 2006 Motzer. Lancet Oncol 2015
28 First-line
29 Approved first-line treatment options for mrcc Phase Control arm PFS (months) OS (months) ORR (%) 1. High-dose IL 2 3 SC IL 2 + IFN α 3.1 vs. 3.1 HR non-reported (NS) 17 vs. 13 (NS) 23.2 vs. 9.9 (CR 8.4%) 2. Sunitinib 3 4. IFN α + bevacizumab 3. Pazopanib 3 noninferiority Cabozantinib (only intermediate & poor-risk patients) 6. Temsirolimus 3 (only poor-risk patients) IFN α 11 vs. 5 HR 0.53 Sunitinib 8.4 vs. 9.5 HR 1.04 IFN α + placebo 10.2 vs. 5.4 HR 0.63 Sunitinib 8.2 vs. 5.6 HR 0.66 IFN - α 5.5 vs. 3.1 HR non-reported 26.4 vs HR vs HR vs vs vs (NS) 30.6 vs vs HR vs. 7.3 HR vs vs Mcdermott. J Clin Oncol Motzer. J Clin Oncol Motzer. NEJM Escudier. Lancet Choueiri. J Clin Oncol Hudes. NEJM 2007
30 Proposed decision-making strategy for the treatment of mrcc Kidney with primary tumor in place? Consider cytoreductive nephrectomy with or without metastasectomy First-line options: Pazopanib Sunitinib IFN-α + Bevacizumab Cabozantinib (only intermediate & poor-risk patients) Temsirolimus (only poor-risk patients) Modified from: Motzer. NEJM 2017
31 Second-line
32 Treatment sequencing New concept Can refer to: 1. Drug combinations 2. Treatment order 3. Both Requires: Drug availability Clinical activity before and after each line Mechanism of resistance Burris 3rd. Cancer Chemother Pharmacol 2013.
33 Treatment sequencing in mrcc retrospective data International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) 2106 Patients Non-clear cell: 12% Median follow-up: 36 months Second-line: 907 (43%) Third-line: 318 (15%) Sequencing VEGF mtor vs. VEGF VEGF HR (adjusted for IMDC risk-groups) (95% IC ) p = 0.10 Alimohamed. Clin Genitourin Cancer 2014
34 Treatment sequencing in mrcc retrospective data 7,438 IMDC patients Sunitinib: 6,519 Pazopanib: 919 No IMDC risk-groups differences ORR Pazopanib 28% Sunitinib 30% Ruiz-Morales. Eur J Cancer. 2016
35 Treatment sequencing in mrcc retrospective data Second-line outcomes: Non-affected by first-line treatment choice 2nd-line Sorafenib Axitinib Everolimus Others 2667 / 6519 (41%) 585 / 2667 (22%) 225 / 2667 (8%) 1194 / 2667 (45%) 673 / 2667 (25%) 290 / 919 (32%) 6 / 290 (2%) 57 / 290 (20%) 154 / 290 (53%) 73 / 290 (25%) Ruiz-Morales. Eur J Cancer. 2016
36 Approved second-line treatment options for mrcc Phase Control arm PFS (months) OS (months) ORR (%) 1. Nivolumab 3 Everolimus 4.6 v 4.4 HR 0.88 (NS) 25 vs HR vs Cabozantinib 3 Everolimus 7.4 vs 3.8 HR vs HR vs Axitinib 3 Sorafenib 6.7 vs 4.7 HR vs HR 0.96 (NS) 23 vs Everolimus 3 Placebo 4.9 vs. 1.9 HR vs HR 0.87 (NS) 1.8 vs 0 5. Sorafenib 3 Placebo 5.5 vs. 2.8 HR vs HR vs Lenvatinib + everolimus 2 Lenvatinib 14.6 v 7.4 HR 0.66 (NS) Everolimus 14.6 vs. 5.5 HR v 19.1 HR 0.68 (NS) 25.5 vs HR v 27 (NS) 43 vs Motzer. NEJM Choueiri. NEJM Motzer. Lancet Oncol Motzer. Lancet Escudier. NEJM Motzer. Lancet 2015
37 Proposed decision-making strategy for the treatment of mrcc Kidney with primary tumor in place? Consider cytoreductive nephrectomy with or without metastasectomy Expected disease control: Maintain VEGFR-inhibitor principle First-line options: Pazopanib Sunitinib IFN-α + Bevacizumab Short-time or non-disease control: Change mechanism of action Second-line option: Cabozantinib (if not previously used) Lenvatinib + Everolimus Cabozantinib (only intermediate & poor-risk patients) Temsirolimus (only poor-risk patients) Second-line option: Nivolumab Modified from: Motzer. NEJM 2017
38 Third-line
39 Third-line of treatment Limited information Based: Experience and availability Poor scientific evidence Motzer. Lancet Oncol 2014
40 Third-line possible treatment options for mrcc Fase Nivolumab 3 28% of patients in both arms had two previous lines of VEGR inhibitors (sunitinib, pazopanib & axitinib) Cabozantinib 3 27% of patients in both arms had two previous lines of VEGR inhibitors (sunitinib, pazopanib & axitinib) Control arm PFS (months) OS (months) ORR (%) Everolimus 4.6 v vs vs. 5 HR 0.88 (NS) HR 0.73 Everolimus 7.4 vs 3.8 HR vs HR vs. 3 Everolimus 3 26% of patients in both arms had two previous lines of VEGR inhibitors (sunitinib & sorafenib) Placebo 4.9 vs. 1.9 HR vs HR 0.87 (NS) 1.8 vs 0 1. Motzer. NEJM Choueiri. NEJM Motzer. Lancet 2008
41 Proposed decision-making strategy for the treatment of mrcc Kidney with primary tumor in place? Consider cytoreductive nephrectomy with or without metastasectomy Expected disease control: Maintain VEGFR-inhibitor principle First-line options: Pazopanib Sunitinib IFN-α + Bevacizumab Short-time or non-disease control: Change mechanism of action Second-line option: Cabozantinib (if not previously used) Lenvatinib + Everolimus Cabozantinib (only intermediate & poor-risk patients) Temsirolimus (only poor-risk patients) Second-line option: Nivolumab Third-line option: Nivolumab Third-line option: Cabozantinib Modified from: Motzer. NEJM 2017
42 Proposed decision-making strategy for the treatment of mrcc Kidney with primary tumor in place? Consider cytoreductive nephrectomy with or without metastasectomy Expected disease control: Maintain VEGFR-inhibitor principle Second-line option: Cabozantinib (if not previously used) Lenvatinib + Everolimus First-line options: Pazopanib Sunitinib IFN-α + Bevacizumab Cabozantinib (only intermediate & poor-risk patients) Temsirolimus (only poor-risk patients) Short-time or non-disease control: Change mechanism of action Second-line option: Nivolumab Third-line option: Nivolumab Modified from: Motzer. NEJM 2017 Fourth-line options (only PFS benefit): Axitinib Everolimus Sorafenib Third-line option: Cabozantinib
43 Non-clear mrcc
44 Non-clear mrcc General approach to treatment, mirrors that for clear-cell mrcc Treatments are generally less effective International guidelines recommend: Enrolling patients in clinical trials for first-line systemic therapy Valenca. Clin Adv Hematol Oncol 2015 Vera-Badillo. Eur Urol 2015
45 Future of treatment sequencing in mrcc Immune biomarker MET biomarker mtor biomarker VEGFR biomarker Nivolumab Cabozantinib Everolimus Temsirolimus Pazopanib Sunitinib Axitinib Lenvatinib Stukalin. Oncology Reviews 2016
46 Take-home messages: mrcc treatment If feasible and justifiable: debulking nephrectomy before systemic therapy FIRST-LINE For good-risk patients, start with: VEGFR inhibitors (pazopanib, sunitinib or IFN-α + bevacizumab) For intermediate-risk patients, start with: Cabozantinib or another VEGR inhibitor For poor-risk patients, start with: Temsirolimus or Cabozantinib
47 Take-home messages: mrcc treatment SECOND-LINE Progression after VEGR inhibitor AND expected disease control: Maintain mechanism of action; use lenvatinib + everolimus or cabozantinib (if not previously used) Progression after VEGR inhibitor AND short-time or non-disease control: Change mechanism of action; use nivolumab
48 Take-home messages: mrcc treatment THIRD-LINE Use cabozantinib or nivolumab; the one that you didn't use previously FOURTH-LINE (only PFS benefit) Axitinib, everolimus or sorafenib NON-CLEAR RENAL CELL CARCINOMA General approach to treatment, mirrors that for clear-cell mrcc
49 Gracias. José M. Ruiz-Morales, MD.
Medical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationPrognostic Factors for mrcc: Relevance in Clinical Practice
Prognostic Factors for mrcc: Relevance in Clinical Practice Daniel Heng MD MPH FRCPC Chair, GU Tumor Group Tom Baker Cancer Center University of Calgary Prognostic Factors Patient Factors Performance Status
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationManagement of High Risk Renal Cell Carcinoma
Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationLinee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationPrognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationpan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr
More informationCANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /
CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study
More informationDose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring
Dose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring Alison Zhang 1, Peter Fox 1, Sally Coulter 4, Val Gebski 5, Bavanthi Balakrishnar 1, Christopher Liddle
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationTreatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationReference No: Author(s) Approval date: June Committee. Operational Date: July Review:
Reference No: Title: Author(s) Systemic anti-cancer therapy (SACT) guidelines for renal cell cancer Dr Alison Clayton Consultant Medical Oncologist & Dr Jane Hurwitz Consultant Medical Oncologist, Cancer
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationRenal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto)
Renal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Nimira Alimohamed (Staff Medical Oncologist, University of Calgary)
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationTreatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationAxitinib in renal cell carcinoma: now what do we do?
Renal Cell Carcinoma Axitinib in renal cell carcinoma: now what do we do? Ian D. Davis Monash University Eastern Health Clinical School, Level 2, Box Hill, Victoria 3128, Australia Correspondence to: Ian
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationAdvances in the Treatment of Renal Cell Carcinoma
Advances in the Treatment of Renal Cell Carcinoma Developed in collaboration Learning Objectives Upon completion, participants should be able to: Identify patients with metastatic renal cell carcinoma
More informationWhy was HOPE 205 a Positive After Years of Negative Studies?
Why was HOPE 205 a Positive After Years of Negative Studies? Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Why do we pursue combinations?
More informationWhat can we expect from running phase III trials: will all of them alter the current treatment algorithm?
What can we expect from running phase III trials: will all of them alter the current treatment algorithm? 8 th European International Kidney Cancer Symposium Budapest, May 2013 Martin Gore PhD FRCP Royal
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationThe Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations
Evidence-Based Series #3-8-4: Section 1 The Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations S. Hotte, T. Waldron,
More informationRenal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation
Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationIto et al. BMC Cancer 2012, 12:337
Ito et al. BMC Cancer 212, 12:337 RESEARCH ARTICLE Open Access C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More informationCLINICAL INVESTIGATION of new agents and combination
Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma By Robert J. Motzer, Jennifer Bacik, Barbara A. Murphy, Paul Russo, and Madhu Mazumdar
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
ipilimumab aligned with patient values. Although few patients had direct experience using this combination agent, patients indicated that side effects associated with nivolumab plus ipilimumab were few
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationSustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma
JOURNAL OF CASE REPORTS 2015;5(1):280-284 Sustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma Chanchal Goswami, Aditi Mandal B. P. Poddar Hospital & Medical Research
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationCytoreductive nephrectomy and its role in the present-day period of targeted therapy
585501TAU0010.1177/1756287215585501Therapeutic Advances in UrologySH Culp review-article2015 Therapeutic Advances in Urology Review Cytoreductive nephrectomy and its role in the present-day period of targeted
More informationComplete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy
Complete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy Is complete remission an achievable goal in mrcc? Lessons from observation Lessons from immunotherapy Current status in
More informationOpinion 26 June 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 26 June 2013 VOTRIENT 200 mg, film-coated tablets B/30 (CIP: 491 313 4) VOTRIENT 400 mg, film-coated tablets B/30
More informationSBRT for lung metastases: Case report
SBRT for lung metastases: Case report Guillermo de Velasco MD, PhD University Hospital 12 de Octubre @H12O_GUCancer @g_develasco Case report 71 years old man Smoker DM 2005 Right radical nephrectomy Histology:
More informationRenal Cell Carcinoma: Navigating a Maze of Choices
Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationTratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
More informationCase(s): How to Deal with Mixed Response Giuseppe Procopio
Case(s): How to Deal with Mixed Response Giuseppe Procopio Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Disclosures Advisory: Astellas, Bayer, GSK Consultant: Pfizer, Novartis Background Mixed
More informationWhen to Treat Beyond Progression with Systemic Therapies? Manuela Schmidinger Medical University of Vienna, Austria
When to Treat Beyond Progression with Systemic Therapies? Manuela Schmidinger Medical University of Vienna, Austria Is Treatment Beyond Progression a Valid Strategy? 1) NO YES? Is Treatment Beyond Progression
More informationOncology A Phase II Study of Presurgical Sunitinib in Patients with Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ
Oncology A Phase II Study of Presurgical Sunitinib in Patients with Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ Axel Bex, Christian Blank, Wim Meinhardt, Harm van Tinteren, Simon
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationScottish Medicines Consortium
Scottish Medicines Consortium sorafenib 200mg tablets (Nexavar ) (No. 321/06) Bayer Plc 6 October 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationProspettive future nel trattamento medico del mrcc. Francesco Massari Oncologia Medica Policlinico S Orsola-Malpighi Bologna
Prospettive future nel trattamento medico del mrcc Francesco Massari Oncologia Medica Policlinico S Orsola-Malpighi Bologna 3 rd YOUNG SPECIALIST RENAL CARE Firenze, 09 Aprile 2016 Renal cell carcinoma
More informationRenal cell cancer: overview and immunochemotherapy
1 Renal cell cancer: overview and immunochemotherapy Vincent Khoo Introduction and epidemiology Kidney cancer is a relatively common urological cancer, accounting for approximately 2% of all adult cancers.
More informationIntroduction. pissn , eissn Cancer Res Treat. 2014;46(4):
pissn 1598-2998, eissn 2005-9256 Original Article http://dx.doi.org/10.4143/crt.2013.154 Open Access Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following
More informationResearch Report. ISSN /17/$ IOS Press and the authors. All rights reserved
Kidney Cancer 1 (2017) 41 47 DOI 10.3233/KCA-160002 IOS Press Research Report 41 Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrrcc) in the Targeted Therapy Era: Results from the International
More informationHow does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy
How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Targeting VHL/HIF in Clear Cell RCC VHL Bevacizumab (Antibody)
More informationImproving our understanding of papillary renal cell carcinoma with integrative genomic analysis
Perspective Page 1 of 5 Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis Parth K. Modi 1, Eric A. Singer 1,2 1 Division of Urology, Rutgers Robert Wood Johnson
More informationINTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA
INTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA Dr. Michael J. Metcalfe PGY-4 Department of Urologic Sciences University of British Columbia October
More informationInterferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy
Original Article - Urological Oncology Korean J Urol 5;56:5-. http://dx.doi.org/./kju.5.56..5 pissn 5-677 eissn 5-675 Interferon treatment for Japanese patients with favorable-risk metastatic renal cell
More informationAtezolizumab Adjuvant Study: Medical Oncologist Perspective. Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center
Atezolizumab Adjuvant Study: Medical Oncologist Perspective Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center Trial overview Key issues Outline Challenges with neoadjuvant therapy Placebo control
More informationThe plan. Overview of clinical trials Current clinical trials in renal cancer Future treatment of renal cancer
Relevant disclosure Bayer - consultancy GSK research funding, consultancy, speaker honoraria Novartis research funding Pfizer research funding, consultancy Roche / Genentech research funding, consultancy
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
More informationSurgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic
More informationCLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12
Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationManagement of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017
consensus statement Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017 This review is CUA-accredited for Section 3 credits of the MOC Program of the RCPSC.
More informationA Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Kim et al. BMC Urology (2016) 16:46 DOI 10.1186/s12894-016-0163-5 RESEARCH ARTICLE Open Access A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with
More informationEfficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.5.1971 Efficacy and Toxicity of Sunitinib in Egyptian Patients with Metastatic Renal Cell Carcinoma RESEARCH ARTICLE Efficacy and Toxicity of Sunitinib in Metastatic
More informationSystemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 216;48(3):192-111 Original Article http://dx.doi.org/1.4143/crt.215.316 Open Access Systemic Treatments for Metastatic Renal Cell Carcinoma: 1-Year Experience
More informationGuidelines on Renal Cell
Guidelines on Renal Cell Carcinoma (Text update March 2009) B. Ljungberg (Chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction Renal cell carcinoma
More informationUpdate on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
Xu and Wu Biomarker Research (2015) 3:5 DOI 10.1186/s40364-015-0030-7 REVIEW Open Access Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma Kevin Y Xu 1 and Shenhong
More informationIntegration of Surgery And Systemic Therapy In The Treatment of
Integration of Surgery And Systemic Therapy In The Treatment of Advanced Renal Cell Carcinoma Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Professorship In Urology
More information